WO2024073849A1 - Composition for treating epilepsy - Google Patents
Composition for treating epilepsy Download PDFInfo
- Publication number
- WO2024073849A1 WO2024073849A1 PCT/CA2023/051315 CA2023051315W WO2024073849A1 WO 2024073849 A1 WO2024073849 A1 WO 2024073849A1 CA 2023051315 W CA2023051315 W CA 2023051315W WO 2024073849 A1 WO2024073849 A1 WO 2024073849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cbd
- composition
- omega
- cannabinoid
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- Epilepsy deleteriously affects millions of people worldwide.
- CBD cannabidiol
- Forming one aspect of the invention is a composition for use in the treatment of epilepsy, the composition comprising at least one cannabinoid and at least one omega-3 fatty acid.
- the composition can be in the form of an oil in water emulsion.
- the at least one cannabinoid is dissolved in the at least one omega-3 fatty acid and the at least one omega-3 fatty acid can define the oil in the oil in water emulsion.
- the at least one cannabinoid can comprise cannabidiol (CBD).
- CBD cannabidiol
- the at least one omega-3 fatty acid can comprise one or more of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA).
- DHA Docosahexaenoic acid
- EPA Eicosapentaenoic acid
- the weight ratio of the at least one cannabinoid to the at least one omega-3 fatty acid can be about 1 :1
- the weight ratio of DHA to EPA can be about 1 :1
- Fig. 1 shows the effects of two preparations of CBD in the MES model in mice.
- composition was prepared with the following ingredients, expressed in weight %
- the CBD was isolate powder.
- the fish oil was unoxidized (fresh) with roughly equal amounts DHA and EPA.
- the stabilizer was LSO NanoStabilizer obtained from Sonomechanics (USA).
- the composition was tested using the Maximal Electroshock Seizure (MES) Model. This is an established procedure to provide an indication of a compound’s ability to prevent seizure spread.
- mice Male, CF-1 male mice (18-25 grams) were used as subjects. They were housed under standard conditions in the vivarium at the CCBR. They were given 2 days (minimum) to acclimate before testing began.
- Drugs and Doses CBD was provided in pure form and in the described composition. Two four-point dose-response curves were done, one for the pure form CBD and one for the described composition. Ten mice were tested at each dose. (Mice were not re-used.) Compounds were injected intraperitoneally. Testing was done 2 hours after injection. Drugs were injected at a constant volume, and were diluted as necessary using a vehicle of 1 :1: 18 (Cremophor : alcohol : saline). Dilution is necessary to achieve volumes large enough for injection. Doses were: 0 (vehicle), 25, 50, 100, 200 mg/kg. A 400 mg/kg dose was added later to extend the standard CBD curve.
- the MES stimulus consisted of 0.2 sec of 60 Hz since-wave current administered at an intensity of 50 mA via corneal electrodes. The percentage of mice protected against the tonic hindlimb extension component of the resulting seizure was measured. Mice were then euthanized following the procedure.
- Toxicity Assessment Ataxia (impaired movement) was assessed using the Loscher scale and was done just before the MES test.
- Figure 1 shows dose-response curve for the antiseizure effects of the two forms of CBD in the MES test in mice.
- the ED50 (effective dose to protect 50% of mice) for regular CBD was 162 mg/kg and the ED50 for the described composition was 105 mg/kg.
- the ED50 for the described formulation was considerably lower. This difference was statistically significant.
- the described composition produced some toxicity at the highest dose, which suggests that more CBD was getting into the brain.
- mice Male, CF-1 male mice (18-25 grams) were used as subjects. They were housed under standard conditions in a vivarium at the University of Toronto (CCBR). They were given 2 days (minimum) to acclimate before testing began.
- CCBR University of Toronto
- Drugs and Doses CBD was provided in the form of: 1) standard CBD isolate, 2) CBD in DHA/EPA without emulsification (2% DHA, 2% EPA, 12% “stabilizer”), 3) CBD emulsified in DHA/EPA to produce larger particles (66.2 nm diameter) and 4) CBD emulsified in DHA/EPA to produce smaller particles (32.7 nm diameter).
- Drugs were injected intraperitoneally at a constant volume, and were diluted as necessary using a vehicle of 1 :1 :18 (Cremophor : alcohol : saline). Dilution is necessary to achieve volumes large enough for injection.
- Doses of CBD ranged from 0 (vehicle) to 400 mg/kg. As in our past studies, the MES stimulus was given 2 hours after injection. Dose-response curves were done for each formulation.
- the MES stimulus consisted of 0.2 sec of 60 Hz since-wave current administered at an intensity of 50 mA via corneal electrodes. The percentage of mice protected against the tonic hindlimb extension component of the resulting seizure was measured. Mice were used only once and euthanized following the procedure.
- Toxicity Assessment Ataxia was assessed using the Loscher scale and was done just before the MES test. Loscher scores of 2-5 were scored a “toxicity present”.
- Statistical Analysis ED50 for protection i.e. , 50% of mice show protection was determined using the Litchfield and Wilcoxon method as implemented by the LW1949 package (ver. 1.1.0) in the RStudio (2022.07.2) programming environment (Adams et al., 2016; Litchfield and Wilcoxon, 1949). ED50’s are presented with 95% confidence intervals. The ED50 for the different formulations were compared using the z-test method described by Austin and Hux (2002). A ztest statistic greater than 1.96 (P ⁇ 0.05) was considered significant when 95% confidence intervals overlapped. The Litchfield/Wilcoxon method could not be applied to the toxicity data for technical reasons, so TD50s were calculated from line plots.
- Figure 2 A, B, C and D shows dose-response curves for the four formulations in the MES test in mice.
- the ED50 (effective dose to protect 50% of mice) for regular CBD in the standard vehicle was 146 mg/kg (Figure 2A).
- the ED50 for CBD in DHA/EPA was tested to determine whether DHA/EPA alone increased CBD’s effectiveness.
- the ED50 for CBD in DHA/EPA without emulsification was 212 mg/kg, which is higher than the ED50 for CBD alone ( Figure 1 B). This difference when compared to CBD in the standard vehicle was not significant, but the findings do not suggest that adding DHA/EPA improves CBD’s anti-seizure effects.
- the ED50 for the large particle emulsification in DHA/EPA was 121 mg/kg, which is lower than the ED50 for CBD alone ( Figure 2C). This difference when compared to CBD in the standard vehicle was not significant.
- the ED50 for the small particle emulsification in DHA/EPA was 102 mg/kg (Figure 2D). This difference when compared to CBD in the standard vehicle was significant.
- FIG. 3 A and B present the toxicity data for CBD alone and CBD emulsified to smaller particles. Neither of the other preparations showed any toxicity up to doses of 400 mg/kg.
- CBD alone showed a TD25 at 400 mg/kg, the highest dose tested. It is speculated that the TD50 would be higher than 400 mg/kg ( Figure 3A).
- the TD50 for CBD emulsified to small particles was 300 mg/kg ( Figure 3B). This is lower than the TD50 for CBD alone, consistent with the idea that more CBD crosses barriers in the small particle formulation.
- the therapeutic index (TD50/ED50) for CBD in the small particle is still about 3, which is in the acceptable range.
- CBD emulsified into small particles was the most effective formulation.
- the ED50 for CBD emulsified into small particles was the lowest, and was significantly different from CBD alone.
- omega-3 fatty acid can be utilized, other stabilizers can be utilized and the weight ratio of fatty acid to cannabinoid can be varied.
- the ratio of cannabinoid to omega 3 can vary between 1.5:1 and 4:1.
- intraperitoneal injection was utilized, other forms are injection could be utilized.
- many drugs introduced intraperitonally can also be introduced orally.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The cunent application relates to a composition comprising at least one cannabinoid and at least one omega- 3 fatty acid in the form of an oil-in-water emulsion; wherein the at least one cannabinoid is dissolved in the at least one omega-3 fatty acid and the at least one omega- 3 fatty acid defines the oil phase of the oil-in-water emulsion. The composition is used for the treatment of epilepsy with improved efficacy compared to regular cannabinoid in standard vehicle.
Description
COMPOSITION FOR TREATING EPILEPSY
Background
Epilepsy deleteriously affects millions of people worldwide.
Many epileptics have seizures that are not readily controlled with conventional medications.
In animal models and clinical trials, cannabinoids, and especially cannabidiol (CBD) have been shown to stop seizures.
Summary of the Invention
Forming one aspect of the invention is a composition for use in the treatment of epilepsy, the composition comprising at least one cannabinoid and at least one omega-3 fatty acid.
According to another aspect, the composition can be in the form of an oil in water emulsion.
According to another aspect, the at least one cannabinoid is dissolved in the at least one omega-3 fatty acid and the at least one omega-3 fatty acid can define the oil in the oil in water emulsion.
According to another aspect, the at least one cannabinoid can comprise cannabidiol (CBD).
According to another aspect, the at least one omega-3 fatty acid can comprise one or more of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA).
According to another aspect, the weight ratio of the at least one cannabinoid to the at least one omega-3 fatty acid can be about 1 :1
According to another aspect, the weight ratio of DHA to EPA can be about 1 :1
Advantages, features and characteristics of the present invention will become apparent upon a review of the following detailed description, with reference to the figures, the latter being briefly described hereinafter.
Brief Description of the Figures
Fig. 1 shows the effects of two preparations of CBD in the MES model in mice.
Detailed Description
A composition was prepared with the following ingredients, expressed in weight %
Fish Oil (DHA & EPA) 3.5%
CBD - 2.0%
Stabilizer - 6.5%
Distilled water - 88.0%
Total 100.0%
The CBD was isolate powder. The fish oil was unoxidized (fresh) with roughly equal amounts DHA and EPA. The stabilizer was LSO NanoStabilizer obtained from Sonomechanics (USA).
The above created an oil in water emulsion as follows:
• particle size 66.2 +/- 0.1 nm
• polydispersity index = 0.107 +/- 0.008
Experimental
The composition was tested using the Maximal Electroshock Seizure (MES) Model. This is an established procedure to provide an indication of a compound’s ability to prevent seizure spread.
Initial Tests
Subjects Male, CF-1 male mice (18-25 grams) were used as subjects. They were housed under standard conditions in the vivarium at the CCBR. They were given 2 days (minimum) to acclimate before testing began.
Drugs and Doses CBD was provided in pure form and in the described composition. Two four-point dose-response curves were done, one for the pure form CBD and one for the described composition. Ten mice were tested at each dose. (Mice were not re-used.) Compounds were injected intraperitoneally. Testing was done 2 hours after injection. Drugs were injected at a constant volume, and were diluted as necessary using a vehicle of 1 :1: 18 (Cremophor : alcohol : saline). Dilution is necessary to achieve volumes large enough for injection. Doses were: 0 (vehicle), 25, 50, 100, 200 mg/kg. A 400 mg/kg dose was added later to extend the standard CBD curve.
MES Procedure The MES stimulus consisted of 0.2 sec of 60 Hz since-wave current administered at an intensity of 50 mA via corneal electrodes. The percentage of mice protected against the tonic hindlimb extension component of the resulting seizure was measured. Mice were then euthanized following the procedure.
Toxicity Assessment Ataxia (impaired movement) was assessed using the Loscher scale and was done just before the MES test.
Results
Antiseizure effects Figure 1 shows dose-response curve for the antiseizure effects of the two forms of CBD in the MES test in mice. The ED50 (effective dose to protect 50% of mice) for regular CBD was 162 mg/kg and the ED50 for the described composition was 105 mg/kg. The ED50 for the described formulation was considerably lower. This difference was statistically significant.
Toxicity No mice showed any signs of toxicity in the standard CBD group at any dose. In the new composition group two subjects showed moderate signs of toxicity (Loscher scale 3) at the highest dose.
Discussion The described composition appeared more effective than regular CBD.
The described composition produced some toxicity at the highest dose, which suggests that more CBD was getting into the brain.
Further Tests
Subjects Male, CF-1 male mice (18-25 grams) were used as subjects. They were housed under standard conditions in a vivarium at the University of Toronto (CCBR). They were given 2 days (minimum) to acclimate before testing began.
Drugs and Doses CBD was provided in the form of: 1) standard CBD isolate, 2) CBD in DHA/EPA without emulsification (2% DHA, 2% EPA, 12% “stabilizer”), 3) CBD emulsified in DHA/EPA to produce larger particles (66.2 nm diameter) and 4) CBD emulsified in DHA/EPA to produce smaller particles (32.7 nm diameter). Drugs were injected intraperitoneally at a constant volume, and were diluted as necessary using a vehicle of 1 :1 :18 (Cremophor : alcohol : saline). Dilution is necessary to achieve volumes large enough for injection. Doses of CBD ranged from 0 (vehicle) to 400 mg/kg. As in our past studies, the MES stimulus was given 2 hours after injection. Dose-response curves were done for each formulation.
MES Procedure The MES stimulus consisted of 0.2 sec of 60 Hz since-wave current administered at an intensity of 50 mA via corneal electrodes. The percentage of mice protected against the tonic hindlimb extension component of the resulting seizure was measured. Mice were used only once and euthanized following the procedure.
Toxicity Assessment Ataxia (impaired movement) was assessed using the Loscher scale and was done just before the MES test. Loscher scores of 2-5 were scored a “toxicity present”. Statistical Analysis ED50 for protection (i.e. , 50% of mice show protection) was determined using the Litchfield and Wilcoxon method as implemented by the LW1949 package (ver. 1.1.0) in the RStudio (2022.07.2) programming environment (Adams et al., 2016; Litchfield and Wilcoxon, 1949). ED50’s are presented with 95% confidence intervals. The ED50 for the different formulations were compared using the z-test method described by Austin and Hux (2002). A ztest statistic greater than 1.96 (P<0.05) was considered significant when 95% confidence intervals overlapped.
The Litchfield/Wilcoxon method could not be applied to the toxicity data for technical reasons, so TD50s were calculated from line plots.
Results
Antiseizure effects Figure 2 A, B, C and D shows dose-response curves for the four formulations in the MES test in mice.
The ED50 (effective dose to protect 50% of mice) for regular CBD in the standard vehicle was 146 mg/kg (Figure 2A).
The ED50 for CBD in DHA/EPA was tested to determine whether DHA/EPA alone increased CBD’s effectiveness. The ED50 for CBD in DHA/EPA without emulsification was 212 mg/kg, which is higher than the ED50 for CBD alone (Figure 1 B). This difference when compared to CBD in the standard vehicle was not significant, but the findings do not suggest that adding DHA/EPA improves CBD’s anti-seizure effects.
The ED50 for the large particle emulsification in DHA/EPA was 121 mg/kg, which is lower than the ED50 for CBD alone (Figure 2C). This difference when compared to CBD in the standard vehicle was not significant.
The ED50 for the small particle emulsification in DHA/EPA was 102 mg/kg (Figure 2D). This difference when compared to CBD in the standard vehicle was significant.
Taken together, the results of the last two experiments suggest that emulsification increases the effectiveness of CBD, and that emulsification to a smaller particle size is better than emulsification to a larger particle size
Toxic Effects Figure 3 A and B present the toxicity data for CBD alone and CBD emulsified to smaller particles. Neither of the other preparations showed any toxicity up to doses of 400 mg/kg.
As indicated, CBD alone showed a TD25 at 400 mg/kg, the highest dose tested. It is speculated that the TD50 would be higher than 400 mg/kg (Figure 3A).
The TD50 for CBD emulsified to small particles was 300 mg/kg (Figure 3B). This is lower than the TD50 for CBD alone, consistent with the idea that more CBD crosses barriers in the small particle formulation. The therapeutic index (TD50/ED50) for CBD in the small particle is still about 3, which is in the acceptable range.
Discussion
CBD emulsified into small particles was the most effective formulation.
The ED50 for CBD emulsified into small particles was the lowest, and was significantly different from CBD alone.
Adding DHA/EPA to CBD without emulsification did not lower the ED50 for CBD.
The results suggest that micro-emulsification increases the potency of CBD, but that adding DHA/EPA to CBD without emulsification does not.
Variations
Whereas a specific composition is shown, variations are possible.
Without limitation in this regard, other sources of omega-3 fatty acid can be utilized, other stabilizers can be utilized and the weight ratio of fatty acid to cannabinoid can be varied. The ratio of cannabinoid to omega 3 can vary between 1.5:1 and 4:1.
Further, whereas intraperitoneal injection was utilized, other forms are injection could be utilized. For example, it is well known that many drugs introduced intraperitonally can also be introduced orally.
Accordingly, the invention should be understood to be limited only by the accompanying claims, purposively construed.
Claims
1. A composition for use in the treatment of epilepsy, the composition comprising at least one cannabinoid and at least one omega-3 fatty acid.
2. The composition of claim 1 , further comprising water and in the form of an oil in water emulsion.
3. The composition of claim 2, wherein the at least one cannabinoid is dissolved in the at least one omega-3 fatty acid and the at least one omega-3 fatty acid defines the oil in the oil in water emulsion.
4. The composition of claim 3, wherein the at least one cannabinoid comprises cannabidiol (CBD).
5. The composition of claim 4, wherein the at least one omega-3 fatty acid comprises one or more of Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA).
6. The composition of claim 4, wherein the weight ratio of the at least one cannabinoid to the at least one omega-3 fatty is acid is about 1 :1
7. The composition of claim 5, wherein the weight ratio of DHA to EPA is about 1 :1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23874143.3A EP4598517A1 (en) | 2022-10-07 | 2023-10-04 | Composition for treating epilepsy |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263414421P | 2022-10-07 | 2022-10-07 | |
| US63/414,421 | 2022-10-07 | ||
| US202263428157P | 2022-11-28 | 2022-11-28 | |
| US63/428,157 | 2022-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024073849A1 true WO2024073849A1 (en) | 2024-04-11 |
Family
ID=90607456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA2023/051315 Ceased WO2024073849A1 (en) | 2022-10-07 | 2023-10-04 | Composition for treating epilepsy |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4598517A1 (en) |
| WO (1) | WO2024073849A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3112583A1 (en) * | 2018-07-09 | 2020-01-16 | New Age Nanotech Llc | Stabilized formulations of cannabinoid compositions |
| CA3110447A1 (en) * | 2018-08-27 | 2020-03-05 | Emerald Health Therapeutics Canada Inc. | Improved cannabinoid bioavailability |
| WO2020123407A1 (en) * | 2018-12-11 | 2020-06-18 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
| WO2021003341A1 (en) * | 2019-07-02 | 2021-01-07 | Ellevet Sciences | Hemp extract for treatment of pain, cancer and epilepsy in animals |
-
2023
- 2023-10-04 WO PCT/CA2023/051315 patent/WO2024073849A1/en not_active Ceased
- 2023-10-04 EP EP23874143.3A patent/EP4598517A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3112583A1 (en) * | 2018-07-09 | 2020-01-16 | New Age Nanotech Llc | Stabilized formulations of cannabinoid compositions |
| CA3110447A1 (en) * | 2018-08-27 | 2020-03-05 | Emerald Health Therapeutics Canada Inc. | Improved cannabinoid bioavailability |
| WO2020123407A1 (en) * | 2018-12-11 | 2020-06-18 | Disruption Labs Inc. | Compositions for the delivery of therapeutic agents and methods of use and making thereof |
| WO2021003341A1 (en) * | 2019-07-02 | 2021-01-07 | Ellevet Sciences | Hemp extract for treatment of pain, cancer and epilepsy in animals |
Non-Patent Citations (3)
| Title |
|---|
| ALESSANDRA MORANO, MARTINA FANELLA, MARIARITA ALBINI, PIERANGELO CIFELLI, ELEONORA PALMA, ANNA TERESA GIALLONARDO, CARLO DI BONAVE: "Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects", NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol. Volume 16, pages 381 - 396, XP093159617, ISSN: 1178-2021, DOI: 10.2147/NDT.S203782 * |
| ALEXIS ARZIMANOGLOU; ULRICH BRANDL; J. HELEN CROSS; ANTONIO GIL‐NAGEL; LIEVEN LAGAE; CECILIE JOHANNESSEN LANDMARK; NICOLA SPECCHIO: "Epilepsy and cannabidiol: a guide to treatment", EPILEPTIC DISORDERS, JOHN LIBBEY EUROTEXT, MONTROUGE, FR, vol. 22, no. 1, 13 March 2020 (2020-03-13), FR , pages 1 - 14, XP072014884, ISSN: 1294-9361, DOI: 10.1684/epd.2020.1141 * |
| GASTON TYLER E.; FRIEDMAN DANIEL: "Pharmacology of cannabinoids in the treatment of epilepsy", EPILEPSY AND BEHAVIOR, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 70, 10 January 2017 (2017-01-10), US , pages 313 - 318, XP085033472, ISSN: 1525-5050, DOI: 10.1016/j.yebeh.2016.11.016 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4598517A1 (en) | 2025-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sarne et al. | Cannabinoids: between neuroprotection and neurotoxicity | |
| Saez et al. | Lipid nanoparticles (SLN & NLC) for delivery of vitamin E: A comprehensive review | |
| JP4828074B2 (en) | Treatment of skin damage using polyenylphosphatidylcholine | |
| EP0265468A1 (en) | DISPERSION OF LIPIDIC SPHERES. | |
| WO2016130686A1 (en) | Stable high concentration strontium compounds and formulations for topical application | |
| JP3854524B2 (en) | Oil-soluble component stabilizing composition, cosmetic containing the composition, and method for stabilizing oil-soluble component | |
| EP0509338A1 (en) | Manufacture and use of stable preparations of small-sized liposomes | |
| WO2016053809A1 (en) | Non-synthetic emulsion-based lipid formulations and methods of use | |
| DE69526450T2 (en) | EMULSION FOR THE ADMINISTRATION AND USE OF A SPHINGOLIPID | |
| WO2024073849A1 (en) | Composition for treating epilepsy | |
| Rosli et al. | Design and physicochemical evaluation of nanostructured lipid carrier encapsulated zingiber zerumbet oil by d-optimal mixture design | |
| CN106727324A (en) | Nano Silver liposome and its preparation method and application | |
| WO2019204630A1 (en) | Cbd nanoencapsulation composition and method of use | |
| Constantinides et al. | Prevention of lipofuscin development in neurons by anti-oxidants | |
| DE19733892C2 (en) | Anti-irradiation method | |
| CA2865777C (en) | 2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor | |
| DE69918152T2 (en) | TREATMENT OF DIGESTIVE DISORDER | |
| Mahmoud et al. | Therapeutic efficacy of praziquantel loaded-chitosan nanoparticles on juvenile Schistosoma mansoni worms in murine model | |
| US12059393B2 (en) | Compositions for topical treatment of radiation dermatitis | |
| RU2817530C1 (en) | Obtaining and using hemp nanoformulation | |
| AU2023218930B2 (en) | Compositions for topical treatment of radiation dermatitis | |
| Imran et al. | Bioactive Polyphenolic Nanoformulations as Potential Therapeutic Agents Against Psoriasis | |
| EP2768471B1 (en) | Aqueous dispersion having a content of lipid nanoparticles, process for production thereof and use thereof | |
| AU2021205603B2 (en) | Preparation and use of cannabis nano-formulation | |
| DE202023100649U1 (en) | Dispersion and preparation for topical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23874143 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023874143 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2023874143 Country of ref document: EP Effective date: 20250507 |
|
| WWP | Wipo information: published in national office |
Ref document number: 2023874143 Country of ref document: EP |